1.Melmed S. Acromegaly. The New England journal of medicine. 1990;322(14):966–77.
2.Wolinski K, Stangierski A, Gurgul E, Brominska B, Czarnywojtek A, Lodyga M, et al. Thyroid lesions in patients with acromegaly - case-control study and update to the meta-analysis. Endokrynologia Polska. 2017;68(1):2–6.
3.Uchoa HB, Lima GA, Correa LL, Vidal AP, Cavallieri SA, Vaisman M, et al. Prevalence of thyroid diseases in patients with acromegaly: experience of a Brazilian center. Arquivos brasileiros de endocrinologia e metabologia. 2013;57(9):685–90.
4.Miyakawa M, Saji M, Tsushima T, Wakai K, Shizume K. Thyroid volume and serum thyroglobulin levels in patients with acromegaly: correlation with plasma insulin-like growth factor I levels. The Journal of clinical endocrinology and metabolism. 1988;67(5):973–8.
5.Tramontano D, Cushing GW, Moses AC, Ingbar SH. Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves’-IgG. Endocrinology. 1986;119(2):940–2.
6.Cannavo S, Squadrito S, Finocchiaro MD, Curto L, Almoto B, Vieni A, et al. Goiter and impairment of thyroid function in acromegalic patients: basal evaluation and follow-up. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2000;32(5):190–5.
7.Jostel A, Ryder WD, Shalet SM. The use of thyroid function tests in the diagnosis of hypopituitarism: definition and evaluation of the TSH Index. Clinical endocrinology. 2009;71(4):529–34.
8.Dietrich JW, Landgrafe-Mende G, Wiora E, Chatzitomaris A, Klein HH, Midgley JE, et al. Calculated Parameters of Thyroid Homeostasis: Emerging Tools for Differential Diagnosis and Clinical Research. Frontiers in endocrinology. 2016;7:57.
9.Herrmann BL, Baumann H, Janssen OE, Gorges R, Schmid KW, Mann K. Impact of disease activity on thyroid diseases in patients with acromegaly: basal evaluation and follow-up. Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association. 2004;112(5):225–30.
10.Kan S, Kizilgul M, Celik B, Beysel S, Caliskan M, Apaydin M, et al. The effect of disease activity on thyroid nodules in patients with acromegaly. Endocrine journal. 2019;66(4):301–7.
11.Roelfsema F, Frolich M. Pulsatile thyrotropin release and thyroid function in acromegalics before and during subcutaneous octreotide infusion. The Journal of clinical endocrinology and metabolism. 1991;72(1):77–82.
12.Inada M, Sterling K. Thyroxine turnover and transport in active acromegaly. The Journal of clinical endocrinology and metabolism. 1967;27(7):1019–27.
13.Sato T, Suzukui Y, Taketani T, Ishiguro K, Masuyama T. Enhanced peripheral conversion of thyroxine to triiodothyronine during hGH therapy in GH deficient children. The Journal of clinical endocrinology and metabolism. 1977;45(2):324–9.
14.Grunfeld C, Sherman BM, Cavalieri RR. The acute effects of human growth hormone administration on thyroid function in normal men. The Journal of clinical endocrinology and metabolism. 1988;67(5):1111–4.
15.Katznelson L, Laws ER, Jr., Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. The Journal of clinical endocrinology and metabolism. 2014;99(11):3933–51.
16.Gasperi M, Martino E, Manetti L, Arosio M, Porretti S, Faglia G, et al. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. Journal of endocrinological investigation. 2002;25(3):240–5.
17.Chanson P, Salenave S. Acromegaly. Orphanet journal of rare diseases. 2008;3:17.
18.Cheung NW, Boyages SC. The thyroid gland in acromegaly: an ultrasonographic study. Clinical endocrinology. 1997;46(5):545–9.
19.Bruchim I, Attias Z, Werner H. Targeting the IGF1 axis in cancer proliferation. Expert opinion on therapeutic targets. 2009;13(10):1179–92.
20.Misaki T, Maciel RM, Tramontano D, Moses AC, Lombardi A, Ingbar SH. Supranormal stimulation of deoxyribonucleic acid synthesis in FRTL5 cells by serum from patients with untreated acromegaly. The Journal of clinical endocrinology and metabolism. 1988;66(6):1227–32.
21.Kurimoto M, Fukuda I, Hizuka N, Takano K. The prevalence of benign and malignant tumors in patients with acromegaly at a single institute. Endocrine journal. 2008;55(1):67–71.
22.Cheung NW, Boyages SC. Somatostatin–14 and its analog octreotide exert a cytostatic effect on GH3 rat pituitary tumor cell proliferation via a transient G0/G1 cell cycle block. Endocrinology. 1995;136(10):4174–81.
23.Ain KB, Taylor KD. Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro. The Journal of clinical endocrinology and metabolism. 1994;78(5):1097–102.
24.Boy C, Heusner TA, Poeppel TD, Redmann-Bischofs A, Unger N, Jentzen W, et al. 68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. European journal of nuclear medicine and molecular imaging. 2011;38(7):1224–36.
25.Klagge A, Krause K, Schierle K, Steinert F, Dralle H, Fuhrer D. Somatostatin receptor subtype expression in human thyroid tumours. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2010;42(4):237–40.
26.Dogansen SC, Salmaslioglu A, Yalin GY, Tanrikulu S, Yarman S. Evaluation of the natural course of thyroid nodules in patients with acromegaly. Pituitary. 2019;22(1):29–36.
27.Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton ML. Hypopituitarism following external radiotherapy for pituitary tumours in adults. The Quarterly journal of medicine. 1989;70(262):145–60.
28.Tan KC, Tso AW, Lam KS. Effect of Sandostatin LAR on serum leptin levels in patients with acromegaly. Clinical endocrinology. 2001;54(1):31–5.
29.Seoane LM, Carro E, Tovar S, Casanueva FF, Dieguez C. Regulation of in vivo TSH secretion by leptin. Regulatory peptides. 2000;92(1–3):25–9.
30.Chan JL, Heist K, DePaoli AM, Veldhuis JD, Mantzoros CS. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. The Journal of clinical investigation. 2003;111(9):1409–21.
31.Dabrowska AM, Tarach JS, Kurowska M, Nowakowski A. Thyroid diseases in patients with acromegaly. Archives of medical science: AMS. 2014;10(4):837–45.
32.Gotzsche LS, Flyvbjerg A, Marshall S, Jorgensen KD, Weeke J. The influence of growth hormone and thyroxine on iodothyronine deiodinase activity in the liver, kidney and brown adipose tissue in hypophysectomized rats. Acta endocrinologica. 1991;125(2):219–26.
33.Eskildsen PC, Kruse A, Kirkegaard C. The pituitary-thyroid axis in acromegaly. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 1988;20(12):755–7.
34.Yoshinari M, Tokuyama T, Kuroda T, Sato K, Okazawa K, Mizokami T, et al. Preserved thyroidal secretion of thyroxine in acromegalic patients with suppressed hypophyseal secretion of thyrotrophin. Clinical endocrinology. 1992;36(4):355–60.
35.Hoermann R, Midgley JE, Giacobino A, Eckl WA, Wahl HG, Dietrich JW, et al. Homeostatic equilibria between free thyroid hormones and pituitary thyrotropin are modulated by various influences including age, body mass index and treatment. Clinical endocrinology. 2014;81(6):907–15.
36.Roelfsema F, Biermasz NR, Frolich M, Keenan DM, Veldhuis JD, Romijn JA. Diminished and irregular thyrotropin secretion with preserved diurnal rhythm in patients with active acromegaly. The Journal of clinical endocrinology and metabolism. 2009;94(6):1945–50.
37.Andersson IJ, Barlind A, Nystrom HC, Olsson B, Skott O, Mobini R, et al. Reduced sympathetic responsiveness as well as plasma and tissue noradrenaline concentration in growth hormone transgenic mice. Acta physiologica Scandinavica. 2004;182(4):369–78.
38.Resmini E, Casu M, Patrone V, Murialdo G, Bianchi F, Giusti M, et al. Sympathovagal imbalance in acromegalic patients. The Journal of clinical endocrinology and metabolism. 2006;91(1):115–20.